skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Sonidegib (Code C82385)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Sonidegib

Definition: An orally bioavailable small-molecule smoothened (Smo) antagonist with potential antineoplastic activity. Sonidegib selectively binds to the hedgehog (Hh)-ligand cell surface receptor Smo, which may result in the suppression of the Hh signaling pathway and, so, the inhibition of tumor cells in which this pathway is abnormally activated. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair. Inappropriate activation of Hh pathway signaling and uncontrolled cellular proliferation, as is observed in a variety of cancers, may be associated with mutations in the Hh-ligand cell surface receptor Smo.

Display Name: Sonidegib

Label: Sonidegib

NCI Thesaurus Code: C82385 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2830069  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
(1,1'-Biphenyl)-3-carboxamide, N-(6-((2R,6S)-2,6-dimethyl-4-morpholinyl)-3-pyridinyl)-2- methyl-4'-(trifluoromethoxy)-, rel-
Smoothened Antagonist LDE225

External Source Codes: 
CAS Registry Number 956697-53-3 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 641974
PDQ Open Trial Search ID 641974 (check for NCI PDQ open clinical trial info)
UMLS CUI C2830069

Other Properties:
     Name Value (qualifiers indented underneath)
Chemical_Formula C26H26F3N3O3
code C82385
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Oral_Smoothened_Antagonist_LDE225
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom